

**CURRICULUM VITAE
BASHIR AL HUSSEIN AL AWAMLH, MD**

Home Address 1330 1st Avenue
 Apt 227
 New York, NY 10021

Office Address Department of Urology, Starr 909A
 525 E 68th Street
 New York, NY 10021

Phone Number 917-436-0788

EDUCATION

2006-2012 Faculty of Medicine, University of Jordan
 Amman, Jordan
 Doctor of Medicine

2022-2024 School of Medicine, Vanderbilt University
 Nashville, TN
 Master of Public Health, Epidemiology track

POSTGRADUATE TRAINING

2012-2013 King Hussein Medical Center
 Amman, Jordan
 Transitional internship

2015-2016 NewYork-Presbyterian Hospital/Weill Cornell Medicine
 New York, NY
 General Surgery Intern

2016-2020 NewYork-Presbyterian Hospital/Weill Cornell Medicine
 New York, NY
 Urology Resident

2020-2021 NewYork-Presbyterian Hospital/Weill Cornell Medicine
 New York, NY
 Chief Resident, Urology

2022-2024 Vanderbilt University Medical Center
 Nashville, TN
 Fellow, Society of Urologic Oncology

LICENSURE AND CERTIFICATES

Tennessee Medical License, exp May 2024, #62385
New York State Medical License exp October 2025, #326647
DEA, exp June 2024, #FA0508993
Board Eligible: American Board of Urology

ACADEMIC APPOINTMENTS

2024-Present	Weill Cornell Medicine/NewYork-Presbyterian New York, NY Assistant Professor of Urology
2022-2024	Vanderbilt University Medical Center, Department of Urology Nashville, TN Clinical Instructor

RESEARCH FUNDING

Current Grants

Assessment of resource utilization following treatment of local prostate cancer using a novel data source
Urology Care Foundation Research Scholar Award
2023-2024: \$40,000
Role: Primary Investigator

RESEARCH EXPERIENCE

2013-2015	Department of Urology, Weill Cornell Medicine New York, NY Clinical Research Assistant
2018-2019	NewYork-Presbyterian Hospital/Weill Connell Medicine New York, NY Douglas Scherr's Lab (dedicated PGY-4 research year)
2020	American Urological Association Early-Career Investigators Workshop

PROFESSIONAL MEMBERSHIPS

2016-Present	American Urological Association
2022-Present	Society of Urologic Oncology
2022-Present	Young Urologic Oncologists

AD HOC REVIEWER

Asian Journal of Urology
Urologic Oncology: Seminars and Original Investigations
Urology
Frontiers in Oncology (Review Editor)
Clinical Genitourinary Cancer
Journal of Homosexuality
Translational Andrology and Urology

Journal of Urology
European Urology
Scientific Reports
Urology Practice
Frontiers in Medicine
Future Oncology
Communications Medicine
Current Oncology
Cancer Medicine
Cancers
Journal of Chemotherapy
Frontiers In Cancer Control And Society

PRESENTATIONS

1. Morbidly and Mortality Conference, Grand Rounds
Weill Cornell Medicine, Department of Urology. October 2020
2. Genitourinary Oncology Ground Rounds
Memorial Sloan Kettering Cancer Center, Department of Urology. March 2021
3. Leveling the Playing Field: Transitioning from Observational to Interventional Studies to Mitigate Disparities in Prostate Cancer Care, Grand Rounds
Weill Cornell Medicine, Department of Urology. June 2023

HONORS AND AWARDS

2020	Weill Cornell Medical Center Alumni Council (CAC) Distinguished Housestaff Award
2020	Cover article of Urology (Volume 138)
2020	Cover article of Urology (Volume 137)
2018	NewYork-Presbyterian Amazing Accomplishment Gold Level Award (Recognizing employees who go above and beyond for patients and families, as well as their coworkers)
2017	Best Poster: General & Epidemiological Trends & Socioeconomics: Practice Patterns, Quality of Life and Shared Decision Making III, AUA

PUBLICATIONS

PEER-REVIEWED JOURNAL ARTICLES

1. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, **Al Hussein Al Awamlh B**, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, Scherr DS, Lotan Y, Vickers A, Shariat SF. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urol Oncol*. 2014 May;32(4):433-40. PMID: 24433754
2. Rieken M, Schubert T, Xylinas E, Kluth LA, Rouprêt M, Trinh QD, Lee RK, Fajkovic H, Novara G, Margulis V, Lotan Y, Martínez-Salamanca JI, Matsumoto K, **Al Hussein Al Awamlh B**, Seitz C, Remzi

- M, Karakiewicz PI, Scherr DS, Briganti A, Bachmann A, Shariat SF. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol*. 2014 Dec;40(12):1693-9. PMID: 24780094
3. **Al Hussein Al Awamlh B**, Lee DJ, Nguyen DP, Green DA, Shariat SF, Scherr DS. Assessment of the quality-of-life and functional outcomes in patients undergoing cystectomy and urinary diversion for the management of radiation-induced refractory benign disease. *Urology*. 2015 Feb;85(2):394-400. PMID: 25623700
 4. Lee DJ, Najjari BB, **Al Hussein Al Awamlh B**, Davison WL, Zaho F, Lee RK. Trends in the utilization of penile prostheses in the treatment of erectile dysfunction. *J Sex Med*. 2015 Jul;12(7):1638-45. PMID: 26096365
 5. Nguyen DP, **Al Hussein Al Awamlh B**, Faltas BM, O'Malley P, Ayangbesan A, Inoyatov IM, Scherr DS. Radical Cystectomy for Bladder Cancer in Patients With and Without a History of Pelvic Irradiation: Survival Outcomes and Diversion-related Complications. *Urology*. 2015 Jul;86(1):99-106. PMID: 26142590
 6. Wang LC, **Al Hussein Al Awamlh B**, Shubert T, Laudano M, Davison W, Zhao F, Hu J, Chughtai B, Lee RK. Trends in Mesh Use for Pelvic Organ Prolapse Repair From the Medicare Database. *Urology*. 2015 Nov;86(5):885-91. PMID: 26344153
 7. Nguyen DP, **Al Hussein Al Awamlh B**, Osterberg EC, Chrystal J, Flynn T, Lee DJ, Scherr DS. Postoperative complications and short-term oncological outcomes of patients aged ≥ 80 years undergoing robot-assisted radical cystectomy. *World J Urol*. 2015 Sep;33(9):1315-21. PMID: 25410374
 8. **Al Hussein Al Awamlh B**, Lee RK, Chughtai B, Donat SM, Sandhu JS, Herr HW. A Cost-effectiveness Analysis of Management of Low Risk Non-Muscle Invasive Bladder Cancer using Office-based Fulguration. *Urology*. 2015 Feb;85(2):381-6. PMID: 25623694
 9. **Al Hussein Al Awamlh B**, Wang LC, Nguyen DP, Rieken M, Lee RK, Lee DJ, Flynn T, Chrystal J, Shariat SF, Scherr DS. Is continent cutaneous urinary diversion a suitable alternative to orthotopic bladder substitute and ileal conduit after cystectomy? *BJU Int*. 2015 Nov;116(5):805-14. PMID: 25168771
 10. **Al Hussein Al Awamlh B**, Nguyen DP, Otto B, O'Malley P, Khan F, Brooks S, Scherr DS. The safety of robot-assisted cystectomy in patients with previous history of pelvic irradiation. *BJU Int*. 2015 Nov;116(5):805-14. PMID: 25168771
 11. Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, **Al Hussein Al Awamlh B**, Lee R, Briganti A, Karakiewicz P, Lotan Y, Roupret M, Rink M, Kluth L, Loidl W, Seitz C, Klatte T, Kramer G, Susani M, Shariat SF. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. *Urol Oncol*. 2016 May;34(5):233.e1-6. PMID: 26973136
 12. Nguyen DP, **Al Hussein Al Awamlh B**, Inoyatov IM, Ayangbesan A, Scherr DS. Recurrence patterns and risk of local and distant recurrence after open and robot-assisted radical cystectomy for bladder cancer: a comparative analysis. *Eur Urol*. 2015 Sep;68(3):399-405. PMID: 25709026
 13. Halpern JA, **Al Hussein Al Awamlh B**, Mittal S, Shoag JE, Hu JC, Lee RK. International Medical Graduate Training in Urology: Are We Missing an Opportunity? *Urology*. 2016 Sep;95:39-46. PMID: 27298199
 14. Nguyen DP, O'Malley P, **Al Hussein Al Awamlh B**, Furrer MA, Mongan NP, Robinson BD, Wang GJ, Scherr DS. Association of Aromatase With Bladder Cancer Stage and Long-Term Survival: New Insights Into the Hormonal Paradigm in Bladder Cancer. *Clin Genitourin Cancer*. 2017. PMID: 27324053

15. Nguyen DP, **Al Hussein Al Awamlh B**, O'Malley P, Khan F, Lewicki PJ, Golombos DM, Scherr DS. Factors Impacting the Occurrence of Local, Distant and Atypical Recurrences after Robot-Assisted Radical Cystectomy: A Detailed Analysis of 310 Patients. *J Urol*. 2016 Nov;196(5):1390-1396. PMID: 27259653
16. Golombos DM, O'Malley P, Lewicki P, Nguyen DP, Stone BV, **Al Hussein Al Awamlh B**, Scherr DS. The impact of socioeconomic status on perioperative complications and oncologic outcomes in patients undergoing radical cystectomy. *World J Urol*. 2017 Jul;35(7):1063-1071. PMID: 27866245
17. Xylinas E, Kluth L, Rieken M, Rouprêt M, **Al Hussein Al Awamlh B**, Clozel T, Sun M, Karakiewicz PI, Gonen M, Shariat SF. External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. *Urol Oncol*. 2017 Jan;35(1):33.e21-33.e26. PMID: 27816402
18. O'Malley PG, Nguyen DP, **Al Hussein Al Awamlh B**, Wu G, Thompson IM, Sanda M, Rubin M, Wei JT, Lee R, Christos P, Barbieri C, Scherr DS. Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. *J Urol*. 2017 Jul;198(1):42-49. PMID: 28115190
19. Xylinas E, Kent M, Dabi Y, Rieken M, Kluth LA, **Al Hussein Al Awamlh B**, Ouzaid I, Pycha A, Compoj E, Svatek RS, Lotan Y, Karakiewicz PI, Holmang S, Shariat SF. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. *Urol Oncol*. 2018 Mar;36(3):89.e1-89.e5. PMID: 29221642
20. Stone BV, Ayangbesan A, Taylor BL, Golombos DM, Lewicki P, **Al Hussein Al Awamlh B**, O'Malley P, Kaplan SA, Scherr DS, Chughtai B. Urinary pH and the risk of recurrence in patients with non-muscle invasive bladder cancer. *Can J Urol*. 2018 Aug;25(4):9407-9412. PMID: 30125520
21. Gross M, **Al Hussein Al Awamlh B**, Shoag JE, Mauer E, Banerjee S, Margolis DJ, Mosquera J, Hamilton A, Schumura MJ, Hu JC. Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions. *BMJ Surg Interv Health Technol*. 2019 Aug 23;1(1):e000010. PMID: 35047774
22. Tzeng M, Cricco-Lizza E, **Al Hussein Al Awamlh B**, Pantuck M, Margolis D, Yu M, Hu J. IDEAL Stage 2a experience with in-office, transperineal MRI/ultrasound software fusion targeted prostate biopsy. *BMJ Surg Interv Health Technol*. 2019 Aug 23;1(1):e000010. PMID: 35047774
23. Van der Mijn J, **Al Hussein Al Awamlh B**, Khan A, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B, Gudas L, Nanus D, Molina A, Del Pizzo J, Scherr D. Validation of risk factors for recurrence of renal cell carcinoma: results from a large single-institution series. *PLoS One*. 2019 Dec 9;14(12):e0226285. PMID: 31815952
24. **Al Hussein Al Awamlh B**, Shoag JE, Ravikumar V, Posada L, Taylor BL, van der Mijn JC, Khan AI, Fainberg J, Al Hussein Alawamleh O, Scherr DS. Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study. *J Urol*. 2019 Dec;202(6):1248-1254. PMID: 31290707
25. **Al Hussein Al Awamlh B**, Ma X, Christos P, Hu J, Shoag J. Active surveillance for Black men with low-risk prostate cancer in the United States. *N Engl J Med*. 2019 Dec 26;381(26):2581-2582. PMID: 31881146
26. Goel S, Shoag JE, Gross MD, **Al Hussein Al Awamlh B**, Robinson B, Khani F, Baltich Nelson B, Margolis DJ, Hu JC. Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2020 Feb;3(1):10-20. PMID: 31492650

27. **Al Hussein Al Awamlh B**, Ma X, Scherr D, Hu J, Shoag J. Temporal changes in demographic and clinical characteristics of men with prostate cancer electing for conservative management in the United States. *Urology*. 2020 Mar;137:60-65. PMID: 31948677
28. **Al Hussein Al Awamlh B**, Margolis D, Gross M, Natarajan S, Ma X; Mosquera J, Hu J. Prostate multiparametric magnetic resonance imaging features following partial gland cryoablation. *Urology*. 2020 Apr;138:98-105. PMID: 31954170
29. **Al Hussein Al Awamlh B**, Marks L, Sonn G, Natarajan S, Fan R, Gross M, Mauer E, Banerjee S, Margolis D, Hu J. Multi-center analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. *Urol Oncol*. 2020 Jul;38(7):637.e9-637.e15. PMID: 32307327
30. Pierce H, Goueli, **Al Hussein Al Awamlh B**, Goel S, Meskawi M, Zorn KC, Te A, Chughtai B. Impact of body mass index on outcomes following anatomic Greenlight laser photoselective vaporization of the prostate. *J Endourol*. 2021 Jan;35(1):39-45. PMID: 32475163
31. **Al Hussein Al Awamlh B**, Ballman K, Ma X, Hu J, Shoag J. Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States. *Prostate Cancer Prostatic Dis*. 2020 Dec;23(4):714-717. PMID: 32661433
32. **Al Hussein Al Awamlh B**, Calderon LP, Shoag J, Patel N, Nicolas J, Scherr DS. The role of surgical experience in patient selection, surgical quality, outcomes in robot assisted radical cystectomy. *Urol Oncol*. 2021 Jan;39(1):6-12. PMID: 33127299
33. **Al Hussein Al Awamlh B**, Basourakos S, Bianco F, Patel N Laviana A, Margolis DJ, Mosquera J, McClure T, Yu M, Hu JC. Feasibility of in-office MRI-targeted partial gland cryoablation for prostate cancer: an IDEAL stage 2A study. *BMJ Surg Interv Health Technol*. 2020 Nov 18;2(1):e000056. PMID: 35047795
34. Khan A, Taylor B, **Al Hussein Al Awamlh B**, Calderon L, Fainberg J, Elahji R, Shoag, J, Scherr D. Survival Outcomes in Neoadjuvant Chemotherapy for High-grade Upper Tract Urothelial Carcinoma: A Nationally Representative Analysis. *Urology*. 2020 Dec;146:158-167. PMID: 32896584
35. Lewicki P, Basourakos S, **Al Hussein Al Awamlh B**, Wu X, Hu J, Schlegel P, Shoag J. Estimating the Impact of COVID-19 on Urology: Data from a Large Nationwide Cohort. *Eur Urol Open Sci*. 2021 Mar;25:52-56. PMID: 33490992
36. **Al Hussein Al Awamlh B**, Shoag J, Posada L, Ma X, Raman J, Shariat S, Scherr D. The consequences of inadvertent radical nephrectomy in the treatment of upper tract urothelial carcinoma. *Urology*. 2021 Aug;154:127-135. PMID: 33766715
37. **Al Hussein Al Awamlh B**, Patel N, Ma X, Calaway A, Ponsky L, Shoag S. Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer across US census regions. *Front Oncol*. 2021 May 19;11:644885. PMID: 34094931
38. Gaffney CDK, Basourakos SP, **Al Hussein Al Awamlh B**, Wu X, Cai PY, Hijaz A, Jaeger I, Lee RK, Shoag JE. Adoption, safety, and retreatment rates of prostatic urethral lift for benign prostatic enlargement. *J Urol*. 2021 Aug;206(2):409-415. PMID: 33793296
39. Hectors S, Chen C, Chen J, Wang J, Gordon S, Yu M, **Al Hussein Al Awamlh B**, Sabuncu M, Margolis D, Hu J. Magnetic Resonance Imaging Radiomics- Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions. *J Magn Reson Imaging*. 2021 Nov;54(5):1466-1473. PMID: 33970516

40. Basourakos S, Lewicki P, Punjani N, Arenas-Gallo C, Gaffney C, Fantus R, **Al Hussein Al Awamlh B**, Schlegel P, Brannigan R, Shoag JE, Halpern J. Practice patterns of vasal reconstruction in a large United States cohort. *Andrologia*. 2021 Dec;53(11):e14228. PMID: 34459018
41. Wilcox Vanden Berg R, Basourakos S, Shoag JE, Scherr D, **Al Hussein Al Awamlh B**. Prostate Cancer Screening for Gay Men in the United States. *Urology*. 2022 May;163:119-125. PMID: 34380053
42. Basourakos S, Tzeng M, Lewicki P, Patel K, **Al Hussein Al Awamlh B**, Venkat S, Shoag JE, Gorin M, Barbieri C, Hu JC. Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer. *Front Oncol*. 2021 May 28;11:676716. PMID: 34123846
43. Venkat S, Khan A, Taylor B, Patel N, **Al Hussein Al Awamlh B**, Posada Calderon L, Fainberg J, Shoag JE, Scherr DS. Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy? *Urol Oncol*. 2022 Mar;40(3):106.e21-106.e29. PMID: 34629282
44. Basourakos S, **Al Hussein Al Awamlh B**, Borregales L, Abrahimi P, Sedrakyan A, Shoag JE, Hu J. comparative population-based analysis of peritoneal carcinomatosis in patients undergoing robotic-assisted and open radical cystectomy. *Int Urol Nephrol*. 2022 Jul;54(7):1513-1519. PMID: 35476175
45. **Al Hussein Al Awamlh B**, Wu X, Barocas DA, Moses KA, Hoffman R, Basourakos SP, Lewicki P, Smelser W, Arenas-Gallo C, Shoag JE. Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States. *Prostate Cancer Prostatic Dis*. 2022 Jul 26. PMID: 35882950
46. Arenas-Gallo C, Owiredu J, Weinstein I, Lewicki P, Basourakos SP, Vince R Jr, **Al Hussein Al Awamlh B**, Schumacher FR, Spratt DE, Barbieri CE, Shoag JE. Race and prostate cancer: genomic landscape. *Nat Rev Urol*. 2022 Sep;19(9):547-561. PMID: 35945369
47. Smelser W, Tallman J, Gupta V, **Al Hussein Al Awamlh B**, Johnsen N, Barocas D, Kline-Quiroz C, Tomlinson C, McEvoy M, Hamilton-Reeves J, Chang S. Implementation of a comprehensive prehabilitation program for patients undergoing radical cystectomy. *Urol Oncol*. 2022 Nov 17:S1078-1439(22)00396-9. PMID: 36404231
48. **Al Hussein Al Awamlh B**, Barocas DA, Zhu A, Tosoian JJ, Ponsky L, Negoita S, Shoag JE. Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018. *JAMA Intern Med*. 2023 Apr 3:e227100. PMID: 37010836
49. **Al Hussein Al Awamlh B**, Wallis CJD, Diehl C, Barocas DA, Beskow LM. The lived experience of prostate cancer: 10-year survivor perspectives following contemporary treatment of localized prostate cancer. *J Cancer Surviv*. 2023 May 12. PMID: 37171717
50. Weinstein I, Wu X, Hill A, Brennan D, Omil-Lima D, Basourakos S, Brant A, Lewicki P, **Al Hussein Al Awamlh B**, Spratt D, Bittencourt L, Scherr D, Zaorsky N, Nagar H, Hu J, Barbieri C, Ponsky L, Vickers S, Shoag JE. Impact of MRI-Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-Analysis. *Eur Urol Oncol*. 2023 May 24. PMID: 37236832
51. Cortese BD, Dusetzina S, Luckenbaugh AN, **Al Hussein Al Awamlh B**, Stimson CJ, Barocas DA, Penson DF, Chang SS, Talwar R. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare. *J Clin Oncol*. 2023 Jun 8. PMID: 37290029
52. Weinstein IC, W Xian, Arenas-Gallo C, Zhu A, Brant A, **Al Hussein Al Awamlh B**, Gaffney C, Lee R, Zell M, Jaeger I, Ponsky L, Shoag J. Adoption and Outcomes of Holmium Laser Enucleation of the Prostate in the United States. *Urology*. 2023 Jun 14;S0090-4295(23)00469-7. PMID: 37328009

53. Cortese B, Dusetzina S, **Al Hussein Al Awamlh B**, Penson DF, Chang SS, Barocas DA, Luckenbaugh A, Scarpato KR, Moses KA, Talwar R. Estimating the Impact of the Inflation Reduction Act on the Out-of-pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer. *Urol Pract*. 2023 Jul 3. PMID: 37409930
54. Arenas-Gallo C, Lewicki P, Prunty M, Brant A, Rhodes S, Basourakos S, Zhu A, **Al Hussein Al Awamlh B**, Shoag JE. Trends, Cost and Predictors of Local Hemostatics Use in Major Urological Surgery. *Urol Pract*. 2023 Jul 27. PMID: 37498305
55. **Al Hussein Al Awamlh B**, Wallis CJD, Penson D, Huang L, Zhao Z, Conwill R, Talwar R, Morgans A, Goodman M, Hamilton A, Wu X, Paddock L, Stroup A, O'Neil B, Koyama T, Hoffman K, Barocas DA. Functional Outcomes After Localized Prostate Cancer Treatment. *JAMA*. 2024 Jan 23;331(4):302-317. PMID: 38261043

EDITORIALS, COMMENTARIES, LETTERS, AND OPINIONS

1. Gross MD, **Al Hussein Al Awamlh B**, Hu JC. Will long term oncologic follow-up make the case for robotic assisted radical cystectomy? Editorial Comment Re: Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. *Transl Androl Urol*. 2018 Dec;7(Suppl 6):S696-S698. PMID: 29784190
2. **Al Hussein Al Awamlh B**, Shoag JE. Genomics and risk stratification in high-risk prostate cancer. *Nat Rev Urol*. 2019 Nov;16(11):641-642. PMID: 31434999
3. **Al Hussein Al Awamlh B**. Alien J1 Physicians in a Pandemic. *JAMA Intern Med*. 2021 Jun 1;181(6):743-744. PMID: 33779678
4. Shoag JE, **Al Hussein Al Awamlh B**, Rajagopalan S. Diabetes Treatment and Control in U.S. Adults. Letter to the Editor Re: Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. *N Engl J Med*. 2021 Sep 2;385(10):e30. PMID: 34469662
5. **Al Hussein Al Awamlh B**, Spratt D, Shoag JE. MRI-Targeted Biopsy in Prostate Cancer Screening. Letter to the Editor Re: MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. *N Engl J Med*. 2021 Nov 25;385(22):2109-2110. PMID: 34818496
6. Lewicki P, Arenas-Gallo C, Basourakos S, **Al Hussein Al Awamlh B**, Venkat S, Scherr D, Shoag JE. Letter to the Editor Re: Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening. *Urology* 2021 Jun 26;S0090-4295(21)00539-2. PMID: 34358591
7. **Al Hussein Al Awamlh B**, Shoag JE. Editorial Comment Re: Prostate Specific Antigen and Biopsy Contamination in the Göteborg-1. Randomized, Population-Based, Prostate Cancer Screening Trial. *J Urol*. 2022 Nov;208(5):1026-1027. PMID: 36065680
8. Ufuah S, Talwar R, **Al Hussein Al Awamlh B**. Editorial Comment Re: Evaluation of a Non-race-based Equation in Predicting Glomerular Filtration Rates Postnephrectomy in a Racially Diverse Cohort. *Urol Pract*. 2023 Sep 1. PMID: 37747926

REVIEW ARTICLES

1. Al Hussein Alawamlh O, **Al Hussein Al Awamlh B**, Lee RK. Metabolic syndrome and voiding dysfunction. Review. *Curr Opin Urol*. 2017 Sep;27(5):403-408. PMID: 28604411

2. Al Hussein Alawamlh O, **Al Hussein Al Awamlh B**, Lee U, Lee R. Overactive bladder in women: an update for primary care physicians. *Current Bladder Dysfunction Reports* volume 15, pages 44–52 (2020).
3. Gross MD, **Al Hussein Al Awamlh B**, Hu JC. Assessing Treatment-Related Toxicity Using Administrative Data, Patient-Reported Outcomes, or Physician-Graded Toxicity: Where Is the Truth? *Semin Radiat Oncol*. 2019 Oct;29(4):333-337. PMID: 31472735
4. **Al Hussein Al Awamlh B**, Al Hussein Alawamlh O, Lee U, Lee R Clinical Updates in Women's Health Care Summary: Overactive Bladder: Primary and Preventive Care Review. *Obstet Gynecol*. 2020 Jan;135(1):253. PMID: 31856122
5. Fainberg J, **Al Hussein Al Awamlh B**, DeRosa A, Chesnut G, Coleman J, Lee T, Ehdaie B. A Systematic Review of Outcomes After Thermal and Nonthermal Partial Prostate Ablation. *Prostate Int*. 2021 Dec;9(4):169-175. PMID: 35059352
6. Samora NL, **Al Hussein Al Awamlh B**, Tosoian JJ. Combined Use of Magnetic Resonance Imaging and Biomarker Testing to Detect Clinically Significant Prostate Cancer. *Urol Clin North Am*. 2023 Feb;50(1):91-107. PMID: 36424086
7. **Al Hussein Al Awamlh B**, Chang SS. Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. *Curr Oncol Rep*. 2022 Dec 26:1-9. PMID: 36571706

INVITED ARTICLES

1. **Al Hussein Al Awamlh B** and Barocas D. AUA2022: PLENARY RECAP Best Way to Do a Prostate Biopsy in 2022: Summary of the AUA Plenary Session. *AUA NEWS* September 2022
2. **Al Hussein Al Awamlh B**, Talwar R, Luckenbaugh A, Scarpato K, Barocas D, Chang S. An Update on the Supply and Production of Bacille Calmette-Guérin. *ASCO Daily News* January 2023
3. Talwar R, **Al Hussein Al Awamlh B**, Cortese B, Luckenbaugh A, Stimson CJ, Chang S. Financial Toxicity Profoundly Affects Patients With Cancer. Novel Prescription Drug Markets Can Alleviate the Burden. *ASCO Daily News* January 2023
4. **Al Hussein Al Awamlh B** and Shoag JE. Healthy Men Should Undergo Baseline PSA Screening: A Call for Clear Guidance. *AUA NEWS* June 2023
5. **Al Hussein Al Awamlh B**, Salami Simpa, Barocas D. Prostate Cancer Diagnostics: Biomarkers, Biopsy Techniques, and MRI. *AUA2023 Highlights in Prostate Cancer* booklet

PEER-REVIEWED ABSTRACTS

1. Otto B, Osterberg EC, **Al Hussein Al Awamlh B**, Green D, Shariat SF, Scherr DS. Impact of prior pelvic radiation complications after robotic assisted radical cystectomy. (American Urological Association Annual Meeting, Orlando, 2014)
2. Winter A, Lee DJ, **Al Hussein Al Awamlh B**, Wang LC, Green D, Scherr DS. Association of lymphovascular invasion at transurethral resection of bladder tumor with long term outcomes in patients undergoing radical cystectomy. (American Urological Association Annual Meeting, Orlando, 2014)
3. Rieken M, Schubert T, Xylinas E, Kluth L, Roupret M, Quoc-dien T, Lee RK, **Al Hussein Al Awamlh B**, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca J, Matsumoto K, Seitz C, Remzi M,

- Karakiewicz P, Scherr D, Brigani A, Bachmann A, Shariat SF. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. (American Urological Association Annual Meeting, Orlando, 2014)
4. Rieken Ma, Shariat SF, **Al Hussein Al Awamlh B**, Kluth L, Crivelli J, Chrystal J, Faison T, Lotan T, Karakiewicz P, Babjuk M, Fajkovic H, Seitz C, Klatte T, Pycha T, Bachmann A, Gönen M, Xylinas E. Comparison of the EORTC tables and the newly introduced EAU categories for risk stratification of patients with non-muscle-invasive bladder cancer. (American Urological Association Annual Meeting, Orlando, 2014)
 5. Rieken Ma, Shariat SF, **Al Hussein Al Awamlh B**, Kluth L, Crivelli J, Chrystal J, Faison T, Lotan T, Karakiewicz P, Babjuk M, Fajkovic H, Seitz C, Klatte T, Pycha T, Bachmann A, Gönen M, Xylinas E. Comparison of the EORTC tables and the newly introduced EAU categories for risk stratification of patients with non-muscle-invasive bladder cancer (European Association of Urology Congress, Stockholm, 2014)
 6. Rieken M, Schubert T, Xylinas E, Kluth L, Roupert M, Quoc-dien T, Lee RK, **Al Hussein Al Awamlh B**, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca J, Matsumoto K, Seitz C, Remzi M, Karakiewicz P, Scherr D, Brigani A, Bachmann A, Shariat SF. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. (European Association of Urology Congress, Stockholm, 2014).
 7. Nguyen DP, **Al Hussein Al Awamlh B**, Wu X, Inoyatov I, Ayangbesan A, Faltas B, Christos P, O'Malley P, and Scherr DS. Recurrence patterns and risk of local and distant recurrence after open and robot-assisted radical cystectomy for bladder cancer: a comparative analysis (Society of Urologic Oncology Annual meeting, Bethesda, 2014)
 8. O'Malley, Hausser N, Nguyen D, **Al Hussein Al Awamlh B**, Mongan N, Robinson B, Wang G, Scherr DS. Aromatase expression in urothelial carcinoma, further evidence of a hormonal effect on oncological factors and outcomes in bladder cancer. (Society of Urologic Oncology Annual meeting, Bethesda, 2014)
 9. Faltas B, Date P, Scherr DS, Nguyen DS, **Al Hussein Al Awamlh B**, O'Malley P, Christos P, Beltran H, M. Nanus D, Tagawa S. Outcomes of pre-operative chemotherapy in bladder cancer patients including node-positive disease (American Society of Clinical Oncology Genitourinary symposium, 2015)
 10. **Al Hussein Al Awamlh B**, Nguyen DP, Faltas B, O'Malley P, Date P, Christos P, Beltran H, Nanus D, Tagawa S. Scherr DS. Outcomes of pre-operative chemotherapy in bladder cancer patients including node-positive disease (European Association of Urology Congress, Madrid, 2015)
 11. Nguyen DP, **Al Hussein Al Awamlh B**, Faltas BM, O'Malley P, Ayangbesan A, Inoyatov IM, Scherr DS. Radical cystectomy for bladder cancer in patients with and without a history of pelvic irradiation: a comparison of survival outcomes and diversion-related complications. (European Association of Urology Congress, Madrid, 2015)
 12. Nguyen DP, **Al Hussein Al Awamlh B**, Inoyatov IM, Ayangbesan A, Scherr DS. Recurrence patterns and risk of local and distant recurrence after open and robot-assisted radical cystectomy for bladder cancer: a comparative analysis. (European Association of Urology Congress, Madrid, 2015)
 13. O'Malley P, **Al Hussein Al Awamlh B**, Nguyen DP, Wu G, Hermann M, Lee R, Christos P, Sanda MG, Thompson IM, Wei JT, Rubin MA, Barbieri CE, and Scherr DS "PCA3 adds predictive value to the PCPT risk calculator amongst non-African American men alone in the Early Detection Research Network (EDRN) (European Association of Urology Congress, Madrid, 2015)

14. Lee DJ, Najjari BB, **Al Hussein Al Awamlh B**, Davison WL, Zaho F, Lee RK. Trends in the utilization of penile prostheses in the treatment of erectile dysfunction. (American Urological Association Annual Meeting, New Orleans, 2015, Podium Presentation)
15. Najari B, Lee D, Davison W, **Al Hussein Al Awamlh B**, Zhao F, Mulhall J, Paduch D, Chughtai B, Lee R. Factors Involved In The Removal Or Replacement Of Penile Prostheses. (American Urological Association Annual Meeting, New Orleans, 2015, Podium Presentation)
16. Wang LC, **Al Hussein Al Awamlh B**, Shubert T, Laudano M, Davison W, Zhao F, Hu J, Chughtai B, Lee RK. Trends in Mesh Use for Pelvic Organ Prolapse Repair (American Urological Association Annual Meeting, New Orleans, 2015)
17. Nguyen DP, **Al Hussein Al Awamlh B**, Faltas BM, O'Malley P, Ayangbesan A, Inoyatov IM, Scherr DS. Radical cystectomy for bladder cancer in patients with and without a history of pelvic irradiation: a comparison of survival outcomes and diversion-related complications. (American Urological Association Annual Meeting, New Orleans, 2015)
18. O'Malley P, **Al Hussein Al Awamlh B**, Nguyen DP, Sanda MG, Thompson IM, Wei JY, Lee R, Rubin MA, Barbieri CE, Hermann MP, and Scherr DS. Location of disease does not impact PCA3's ability to predict cancer on biopsy (American Urological Association Annual Meeting, New Orleans, 2015)
19. O'Malley P, **Al Hussein Al Awamlh B**, Sarkisian AM, Jin S, Nguyen DP, Lee R, Scherr DS, Barbieri CE, and Hermann MP Potential for failure of focal prostate hemi-ablation strategies (American Urological Association Annual Meeting, New Orleans, 2015)
20. Nguyen DP, **Al Hussein Al Awamlh B**, Inoyatov IM, Ayangbesan A, Scherr DS. Recurrence patterns and risk of local and distant recurrence after open and robot-assisted radical cystectomy for bladder cancer: a comparative analysis. (American Urological Association Annual Meeting, New Orleans, 2015)
21. Golombos D, O'Malley P, Lewicki P, **Al Hussein Al Awamlh B**, Nguyen D, Inoyatov I, Scherr D Health care disparities and post discharge complications in patients undergoing radical cystectomy. (American Urological Association Annual Meeting, San Diego, 2016, Podium Presentation)
22. O'Malley P, Golombos D, Lewicki P, **Al Hussein Al Awamlh B**, Christos P, Thompson I, Sanda M, Wei J, Rubin M, Barbieri C, Scherr D. PCA3 and T2:ERG add further predictive and clinical benefit to the detection of prostate cancer in men of various ages in the Early Detection Research Network (EDRN).(American Urological Association Annual Meeting, San Diego, 2016)
23. **Al Hussein Al Awamlh B**, Wang L, Stone B, Bedretdinova D, Forde J, Li P, Chughtai B, Lee R. Trends and failure rates in the medical treatment of pelvic organ prolapse for Medicare patients. (American Urological Association Annual Meeting, San Diego, 2016)
24. **Al Hussein Al Awamlh B**, Nguyen D, Shulster M, O'Malley P, Golombos D, Lewicki D, Stone B, Scherr D. Do bladder cancer patients with clinically metastatic lymph node disease benefit from radical cystectomy? (American Urological Association Annual Meeting, San Diego, 2016, Podium Presentation)
25. Bernstein A, **Al Hussein Al Awamlh B**, Golan R, Dinerman B, Fainberg J, Hu J. Underutilization of palliative services in advanced genitourinary malignancies. (American Urological Association Annual Meeting, Boston, 2017)
26. Goueli R, **Al Hussein Al Awamlh B**, Thomas D, Zorn K , Te A, Chughtai B. The Effect Of Obesity On Outcomes Of Laser Photovaporization Of The Prostate (American Urological Association Annual Meeting, Boston, 2017)

27. Ayangbesan A, Taylor B, **Al Hussein Al Awamlh B**, Lewicki P, Nguyen D, Golombos D, Barlow L, Scherr D. Continent Cutaneous Urinary Diversion Is A Viable Option for Elderly Patients Undergoing Radical Cystectomy (American Urological Association Annual Meeting, Boston, 2017)
28. Taylor B, **Al Hussein Al Awamlh B**, Shoag J, Xia L, Patel N, Stark T, Nicolas J, Scherr D. Does Robotic Cystectomy Achieve Oncologic Efficacy for Locally Advanced Bladder Cancer? (American Urological Association Annual Meeting, San Francisco, 2018)
29. **Al Hussein Al Awamlh B**, Khan A, Taylor B, Calderon P, Fainberg J, Stark T, Nicolas J, Scherr D. Do We Harm Bladder Cancer Patients Who Do Not Respond to Neoadjuvant Chemotherapy? (American Urological Association Annual Meeting, Chicago, 2019)
30. **Al Hussein Al Awamlh B**, Marks L, Sonn G, Gross M, Hu J. Can We Better Understand PI-RADS 3 Lesions and Avoid Unnecessary Biopsies? (American Urological Association Annual Meeting, Chicago, 2019)
31. **Al Hussein Al Awamlh B**, Shoag J, Fainberg J, Al Hussein Alawamlh O, Douglas Scherr. Association of Smoking and Death Form Urologic Malignancies: A Contemporary Assessment In A Nationally Representative Cohort (American Urological Association Annual Meeting, Chicago, 2019)
32. Posada L, **Al Hussein Al Awamlh B**, Fainberg J, Van Der Mijn, Taylor, Alshak M, Elahjji R, Pierce H, Scherr Ds. African Americans and renal cell carcinoma: is the pathophysiologic process different? (Society Of Urologic Oncology Annual Meeting, Washington DC, 2019)
33. **Al Hussein Al Awamlh B**, Schaeffer E, Nyame Y, Ma X, Hu J, Shoag J Use of active surveillance for black men with low-risk prostate cancer (Society of Urologic Oncology Annual Meeting, Washington DC, 2019)
34. **Al Hussein Al Awamlh B**, Posada L, Khan A, Shoag J, Cai P, Gaffney C, Scherr D. The role of surgical experience in patient selection, surgical quality and outcomes in robot-assisted radical cystectomy (Society of Urologic Oncology Annual meeting, Washington DC, 2019)
35. **Al Hussein Al Awamlh B**, Posada L, Khan A, Shoag J, Cai P, Gaffney C, Scherr D. The role of surgical experience in patient selection, surgical quality and outcomes in robot-assisted radical cystectomy (Society of Urologic Oncology Annual meeting, Washington DC, 2019)
36. **Al Hussein Al Awamlh B**, Shoag J, Posada L, Ma X, Raman J, Shariat SF, Scherr DS. Implications of inadvertent radical nephrectomy instead of nephroureterectomy in the treatment of upper tract urothelial carcinoma. (American Urological Association Annual Meeting, virtual meeting, 2020)
37. Khan A, Taylor B, **Al Hussein Al Awamlh B**, Calderon L, Fainberg J, Shoag J, Scherr D. Redefining the obesity paradox in renal cell carcinoma. (American Urological Association Annual Meeting, virtual meeting, 2020, Podium Presentation)
38. Khan A, Taylor B, **Al Hussein Al Awamlh B**, Calderon L, Fainberg J, Shoag J, Scherr D. Stratifying size within renal cell carcinoma staging groups does not correlate to outcomes; a single institution experience with 870 patients over 15 years (American Urological Association Annual Meeting, virtual meeting, 2020)
39. Shoag J, Cai P, Gaffney C, **Al Hussein Al Awamlh B**, Ma X, Barbieri C. Age-dependent prevalence of prostate cancer genomic subtypes predicted by inverse probability weighting (American Urological Association Annual Meeting, virtual meeting, 2020)

40. Calderon L, **Al Hussein Al Awamlh B**, Fainberg J, Khan A, Enobakhare O, Scherr D. A pilot study to investigate the use of video visits in reducing readmissions after major urologic surgery (American Urological Association Annual Meeting, virtual meeting, 2020, Podium Presentation)
41. Calderon L, **Al Hussein Al Awamlh B**, Khan A, Van der Mijn J, Shoag J, Taylor B, Scherr D. Renal surgery rates for kidney cancer at minority serving hospitals (American Urological Association Annual Meeting, virtual meeting, 2020)
42. Khan A, Taylor B, **Al Hussein Al Awamlh B**, Calderon L, Fainberg J, Shoag J, Scherr D. Does neoadjuvant chemotherapy diminish the gender disparity in bladder cancer survival after radical cystectomy? (American Urological Association Annual Meeting, virtual meeting, 2020)
43. **Al Hussein Al Awamlh B**, Ma X, Cai P, Patel N, Basourakos S, Gaffney C, Wilcox Vanderberg R, Fainberg J, Scherr D, Hu J, Shoag J. Temporal changes in demographic and clinical characteristics of men with prostate cancer electing for active surveillance in the US (American Urological Association Annual Meeting, virtual meeting, 2020)
44. Basourakos B, Posada L, **Al Hussein Al Awamlh B**, Taylor B, Scherr D. Palliative care in patients with advanced bladder cancer in the US (American Urological Association Annual Meeting, virtual meeting, 2020)
45. **Al Hussein Al Awamlh B**, Shoag J, Posada L, Ma X, Raman J, Shariat SF, Scherr DS. Implications of inadvertent radical nephrectomy instead of nephroureterectomy in the treatment of upper tract urothelial carcinoma (European Association of Urology Congress, virtual meeting, 2020)
46. **Al Hussein Al Awamlh B**, Lewicki P, Basourakos S, Wu X, Hu J, Shoag J. Real-world active surveillance implementation in black men with prostate cancer in the US (American Urological Association Annual Meeting, virtual meeting, 2021, Podium Presentation)
47. Weinstein I, Wu X, Hill A, Brennan D, Omil-Lima D, Basourakos S, Brant A, Lewicki P, **Al Hussein Al Awamlh B**, Spratt D, Bittencourt L, Scherr D, Zaorsky N, Nagar H, Hu J, Barbieri C, Ponsky L, Vickers A, Shoag J. Impact of MRI-targeting on pathologic upgrading and downgrading at prostatectomy: A Systematic Review and Meta-analysis (American Urological Association Annual Meeting, 2023, Chicago Podium Presentation)
48. Weinstein I, Arenas-Gall C, Wu X, Omil-Lima D, Brant A, **Al Hussein Al Awamlh B**, Gaffney C, Jaeger I, Shoag J. Adoption, Safety, And Efficacy Of HoLEP For Benign Prostatic Hyperplasia In The United States (American Urological Association Annual Meeting, Chicago, 2023)
49. Arenas-Gallo C, Lewicki P, Prunty M, Brant A, Rhodes S, Basourakos S, Zhu A, Weinstein I, **Al Hussein Al Awamlh B**, Shoag J. Trends, Outcomes, And Costs Of Hemostatic Utilization For Major Urologic Surgery (American Urological Association Annual Meeting, Chicago, 2023)